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Purpose or Objective 
To evaluate the changes in immune-cell phenotype in 
peripheral blood following intraoperative radiotherapy 
(IORT) in breast cancer patients. 
Material and Methods 
45 patients were classified in three groups of treatment as 
follows: Group A (Lumpectomy and Intrabeam exclusive), 
Group B (Lumpectomy and Intrabeam followed by EBRT 
40.05 Gy in 15 fractions of 2.67 Gy) and Group C 
(Lumpectomy and EBRT 40.05 Gy in 15 fractions of 2.67 Gy 
+/- EBRT boost 9 Gy in 3 fractions). For each group, 
peripheral blood mononuclear cells (PBMCs) were isolated 
from heparinized venous blood samples collected before 
treatment and during different time points after 
treatment: before lumpectomy, 48 hours after IORT or 
EBRT, and 3 and 10 weeks after radiation treatment was 
completed. Peripheral blood populations of cytotoxic T-
cells (CTL), helper T-cells, Natural Killer cells (NK), 
regulatory T-cells (Treg) and Myeloid Derived Suppressor 
cells (MDSC) were measured using flow cytometry. Cell 
phenotypes were evaluated using the FACS Navios system 
(BeckmanCoulter). Data were analyzed using FlowJo 
software (Tree Star Inc., Ashland, OR, USA). 
Results 
30 patients were included: 11, 15 and 4 patients for Group 
A, B and C respectively. For group A and B, the number of 
CTL increased three weeks after IORT (60.20% basal vs 
67.10%) and EBRT (66.50% basal vs 71.30%) respectively. 
In contrast, for the control group (group C), a decrease in 
CTL was seen (64.35% vs 61.50%). In group A the number 
of NK cells increased after treatment (46.20% basal vs 
59.20%), while in group B (42.90% basal vs 36.35%) and 
group C (56.80% basal vs 38.40%), we observed a NK 
decrease. For Treg we had mixed results which were hard 
to interpret. For Group A we saw a decrease during 
treatment (1.54% basal vs 1.44%) while for Group B we 
observed an increase of these cells (2.0% basal vs 2.75%). 
After 3 weeks, this tendency was reverted.  For Group C, 
we observed an increase during treatment (1.45% basal vs 
2.87%). For the MDSC panel, for granulocytes we observed 
a decrease in group A (6.44% basal vs 5.78%) and an 
increase in both group B (7.90% basal vs 10.31%) and group 
C (7.65% basal vs 10.20%) after 10 weeks. For Monocytes, 
in group A we observed the number of activated 
monocytes stable (8.95% basal 9.13%), whereas in group B 
and C we saw an increase after EBRT.  
Conclusion 
These results suggest that high doses per fraction would 
play an important role in CT, NK cells but not on the Treg 
and monocytes immunosuppression cells. Deciphering 
immune responses to treatment in breast cancer patients 
might introduce new useful biomarkers for treatment 
choices in the future. 
